Compare Nucor Corporation (NUE) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Novavax Inc — how do they compare? Nucor Corporation trades at $269.5 (market cap $61.93B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Nucor Corporation is far larger — about 47.3× Novavax Inc's market cap, and Nucor Corporation pays a 0.82% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NUE | NVAX | |
|---|---|---|
Market Cap | $61.93B | $1.31B |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $11.19 |
52-Week Low | $131.78 | $6.22 |
Enterprise Value | $66.34B | $889.30M |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $274.61, up 0.73% today, with a bullish technical outlook and strong earnings beats in Q1 and Q2 2026. The stock shows robust fundamentals with a P/E of 21.7 and net income margin of 7.99%, supported by record steel shipments and higher prices. Recent news highlights its position near buy points and resilience in industrial demand.
Outlook is positive with analyst consensus favoring buy ratings (59.37%) and a $279.63 price target. Risks include cyclical steel demand and tariff impacts, but earnings growth and institutional support provide upside potential for investors seeking exposure to industrial recovery.
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
